A study from researchers at the University of Birmingham found that a highly purified CBD isolate poses no genotoxic risk when tested using widely accepted toxicology standards.
CBD Isolate.
Published in the journal Pharmaceutical Biology, the study involved both a bacterial reverse mutation test (Ames test) and an in vitro mammalian cell micronucleus assay. These tests were conducted on a CBD isolate containing over 97% cannabidiol, along with its lipid carrier. Researchers followed OECD guidelines 471 and 487, which are internationally recognized protocols for evaluating genetic toxicity.
Results showed that the CBD isolate was non-mutagenic in the Ames test and did not lead to a statistically significant increase in micronucleated cells in the mammalian cell assay. These findings suggest the compound does not damage genetic material at doses expected in foods and supplements.
“In summary, the potential genotoxicity of the CBD test substance was assessed using a mammalian cell micronucleus test and Ames test”, states the study. “These tests respectively assess chromosomal damage and base changes, or frameshift mutations in the genome. Application of these assays to the CBD test substance did not produce any evidence of genotoxic effects, findings that are consistent with other studies.”
Researchers concude by saying “These studies confirm that this CBD rich isolate in combination with its carrier, are unlikely to post any genotoxic hazard at exposure levels expected in foods.”
For the full text of the study, click here.
